What are the instructions for using ixazomib and dexamethasone?

Ixazomib, when used in combination with dexamethasone, is indicated primarily for the treatment of adults with multiple myeloma who have received at least one prior therapy.

The recommended dose of ixazomib is 4 mg per time. In the treatment cycle of 28 days, administration was performed on days 1, 8 and 15, that is, administration was administered 1 times per week. It should be taken at least 1 hour before a meal or at least 2 hours after a meal to ensure optimal absorption of the drug. At the same time, the timing of each dose should be approximately the same. Take the whole capsule with water. Do not crush, chew or open the capsule to avoid affecting the effect of the medicine.

The recommended dose of dexamethasone is 40 mg per session. In the treatment cycle of 28 days, on days 1, 8, 15and 22 days, that is, 1 dosing times per week, but different from the dosing days of ixazomib. Dexamethasone is usually taken with a meal to increase its bioavailability.

During treatment, the patient's blood routine, liver and kidney function and other indicators should be regularly monitored to evaluate the impact of the drug on the body. Particularly for hematological toxicities such as thrombocytopenia and neutropenia, platelet counts should be monitored at least monthly and treatment options should be adjusted based on monitoring results.

Pay attention to observe whether the patient has common adverse reactions of ixazomib or dexamethasone, such as diarrhea, nausea, vomiting, rash, etc., and deal with them in time. For serious adverse reactions, such as allergic reactions, reversible posterior encephalopathy syndrome, etc., you should seek medical attention immediately.

When used together with dexamethasone, ixazomib may increase the risk of certain adverse reactions or affect drug metabolism. Therefore, doctors should be informed of all drugs being used, especially drugs that may affect the metabolism of ixazomib or dexamethasone. Also, avoid interactions with CYP3AStrong inducers (such as rifampicin) should be used together to avoid reducing the efficacy of ixazomib.

For special groups such as elderly patients and patients with liver and kidney function impairment, the doses of ixazomib and dexamethasone should be adjusted according to specific conditions. For example, in patients with severe hepatic or renal impairment, it is recommended that the dose of ixazomib be reduced to 3 mg.